Announcements in Conjunction With Theratechnologies Annual Meeting

MONTREAL, July 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of shareholders.

As part of the meeting, shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and elected KPMG LLP, as the Company’s auditors for the current fiscal year.

All candidates proposed for the position of directors were elected in the following proportion:   

	# IN FAVOUR	% IN FAVOUR	# ABSTENTION	% ABSTENTION
Sheila M. Frame	21,638,746	96.64	752,700	3.36
Gérald A. Lacoste	21,397,231	95.56	994,215	4.44
Paul Lévesque	22,215,562	99.21	175,884	0.79
Gary Littlejohn	21,547,956	96.23	843,490	3.77
Paul Pommier	20,902,079	93.35	1,489,367	6.65
Dawn Svoronos	21,660,353	96.73	731,093	3.27
Dale MacCandlish-Weil	21,675,859	96.80	715,587	3.20

In addition, shareholders approved the proposed amendments to By-Law No.3, the adoption of By-Law No.4, being an advance notice by-law, and an increase and replenishment of the number of common shares available for issuance under the share option plan.

Ms. Dawn Svoronos and Mr. Paul Lévesque, respectively Chair of the Board and President and CEO of Theratechnologies, addressed people who attended the virtual meeting.

“Above and beyond growing its revenue in the last year, Theratechnologies is now a very different company based on its amazing pipeline. While the team continues to work on improving and optimizing revenues from our commercial assets, it is now building a long-term future for Theratechnologies through the development of a very promising pipeline,” said Dawn Svoronos, Chair of the Board, Theratechnologies Inc.